Lantheus Holdings, Inc. (NASDAQ:LNTH) Holdings Decreased by Stanley Laman Group Ltd.

Stanley Laman Group Ltd. lowered its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6.3% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 61,236 shares of the medical equipment provider’s stock after selling 4,100 shares during the quarter. Stanley Laman Group Ltd.’s holdings in Lantheus were worth $5,478,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Janus Henderson Group PLC grew its stake in shares of Lantheus by 7.7% in the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock valued at $393,844,000 after purchasing an additional 257,022 shares during the period. Geode Capital Management LLC increased its position in shares of Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after buying an additional 32,551 shares in the last quarter. Reinhart Partners LLC. increased its position in shares of Lantheus by 9.9% in the 4th quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock valued at $122,280,000 after buying an additional 123,282 shares in the last quarter. Swedbank AB increased its holdings in Lantheus by 53.3% during the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock worth $99,054,000 after purchasing an additional 385,000 shares in the last quarter. Finally, Portolan Capital Management LLC increased its holdings in Lantheus by 6.1% during the 3rd quarter. Portolan Capital Management LLC now owns 670,881 shares of the medical equipment provider’s stock worth $73,629,000 after purchasing an additional 38,776 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

Lantheus stock opened at $82.10 on Thursday. The stock has a market cap of $5.71 billion, a P/E ratio of 13.66 and a beta of 0.44. The firm’s fifty day moving average price is $91.76 and its 200-day moving average price is $98.13. Lantheus Holdings, Inc. has a fifty-two week low of $54.69 and a fifty-two week high of $126.89.

Insider Buying and Selling at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on LNTH shares. Truist Financial reiterated a “buy” rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. The Goldman Sachs Group began coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target for the company. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $131.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.